Bacterial Skin Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major bacterial skin diseases markets are expected to exhibit a CAGR of 6.56% during 2024-2034.
The bacterial skin diseases market has been comprehensively analyzed in IMARC's new report titled "Bacterial Skin Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bacterial skin diseases, also known as bacterial skin infections, are a group of dermatological conditions caused by the invasion and proliferation of harmful bacteria on the skin's surface or within its deeper layers. These infections can lead to a wide range of symptoms, depending on the specific bacteria involved and the affected area. Common indications include redness, swelling, pain, itching, and the formation of pus-filled lesions or sores. In some cases, bacterial skin diseases can cause more severe symptoms, such as fever, cellulitis (a spreading infection of the skin and underlying tissues), or abscess formation. The diagnosis of these conditions typically involves a thorough physical examination by a healthcare professional. They may examine the affected area, take a medical history, and inquire about any recent injuries or exposures that could have contributed to the infection. In some cases, a sample of the infected tissue or fluid may be collected for laboratory testing to identify the specific bacteria responsible and guide treatment decisions.
The increasing prevalence of infections that can result from direct contact with the bacteria or from the overgrowth of bacteria that are normally present on the skin is primarily driving the bacterial skin diseases market. In addition to this, the inflating utilization of advanced wound care therapies on account of their several advantages, like promoting faster healing, preventing bacterial colonization, and reducing the risk of complications, is also creating a positive outlook for the market. Moreover, the widespread adoption of telemedicine and digital healthcare solutions that have facilitated quicker diagnoses and remote monitoring, thereby enhancing patient outcomes and accessibility to healthcare services, is further propelling the market growth. Apart from this, the rising application of probiotic treatments, aimed at restoring the natural skin flora and bolstering the skin's defense mechanisms against pathogens, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of light-based therapies, which utilize certain wavelengths to ensure rapid recovery and reduce the chances of recurrent infections, is also augmenting the market growth. Furthermore, the ongoing developments in bacteriophage therapy, since it involves using viruses to specifically target and eliminate harmful bacteria without disturbing the natural flora, are expected to drive the bacterial skin diseases market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the bacterial skin diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bacterial skin diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bacterial skin diseases market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bacterial skin diseases market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bacterial skin diseases market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bacterial skin diseases marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report:
Market Insights
How has the bacterial skin diseases market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bacterial skin diseases market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bacterial skin diseases market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of bacterial skin diseases across the seven major markets?
What is the number of prevalent cases (2018-2034) of bacterial skin diseases by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of bacterial skin diseases by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with bacterial skin diseases across the seven major markets?
What is the size of the bacterial skin diseases patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bacterial skin diseases?
What will be the growth rate of patients across the seven major markets?
Bacterial Skin Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bacterial skin diseases drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bacterial skin diseases market?
What are the key regulatory events related to the bacterial skin diseases market?
What is the structure of clinical trial landscape by status related to the bacterial skin diseases market?
What is the structure of clinical trial landscape by phase related to the bacterial skin diseases market?
What is the structure of clinical trial landscape by route of administration related to the bacterial skin diseases market?
The bacterial skin diseases market has been comprehensively analyzed in IMARC's new report titled "Bacterial Skin Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bacterial skin diseases, also known as bacterial skin infections, are a group of dermatological conditions caused by the invasion and proliferation of harmful bacteria on the skin's surface or within its deeper layers. These infections can lead to a wide range of symptoms, depending on the specific bacteria involved and the affected area. Common indications include redness, swelling, pain, itching, and the formation of pus-filled lesions or sores. In some cases, bacterial skin diseases can cause more severe symptoms, such as fever, cellulitis (a spreading infection of the skin and underlying tissues), or abscess formation. The diagnosis of these conditions typically involves a thorough physical examination by a healthcare professional. They may examine the affected area, take a medical history, and inquire about any recent injuries or exposures that could have contributed to the infection. In some cases, a sample of the infected tissue or fluid may be collected for laboratory testing to identify the specific bacteria responsible and guide treatment decisions.
The increasing prevalence of infections that can result from direct contact with the bacteria or from the overgrowth of bacteria that are normally present on the skin is primarily driving the bacterial skin diseases market. In addition to this, the inflating utilization of advanced wound care therapies on account of their several advantages, like promoting faster healing, preventing bacterial colonization, and reducing the risk of complications, is also creating a positive outlook for the market. Moreover, the widespread adoption of telemedicine and digital healthcare solutions that have facilitated quicker diagnoses and remote monitoring, thereby enhancing patient outcomes and accessibility to healthcare services, is further propelling the market growth. Apart from this, the rising application of probiotic treatments, aimed at restoring the natural skin flora and bolstering the skin's defense mechanisms against pathogens, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of light-based therapies, which utilize certain wavelengths to ensure rapid recovery and reduce the chances of recurrent infections, is also augmenting the market growth. Furthermore, the ongoing developments in bacteriophage therapy, since it involves using viruses to specifically target and eliminate harmful bacteria without disturbing the natural flora, are expected to drive the bacterial skin diseases market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the bacterial skin diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bacterial skin diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bacterial skin diseases market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bacterial skin diseases market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bacterial skin diseases market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bacterial skin diseases marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report:
Market Insights
How has the bacterial skin diseases market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bacterial skin diseases market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bacterial skin diseases market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of bacterial skin diseases across the seven major markets?
What is the number of prevalent cases (2018-2034) of bacterial skin diseases by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of bacterial skin diseases by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with bacterial skin diseases across the seven major markets?
What is the size of the bacterial skin diseases patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bacterial skin diseases?
What will be the growth rate of patients across the seven major markets?
Bacterial Skin Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bacterial skin diseases drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bacterial skin diseases market?
What are the key regulatory events related to the bacterial skin diseases market?
What is the structure of clinical trial landscape by status related to the bacterial skin diseases market?
What is the structure of clinical trial landscape by phase related to the bacterial skin diseases market?
What is the structure of clinical trial landscape by route of administration related to the bacterial skin diseases market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BACTERIAL SKIN DISEASES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BACTERIAL SKIN DISEASES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BACTERIAL SKIN DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BACTERIAL SKIN DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BACTERIAL SKIN DISEASES - UNMET NEEDS
10 BACTERIAL SKIN DISEASES - KEY ENDPOINTS OF TREATMENT
11 BACTERIAL SKIN DISEASES - MARKETED PRODUCTS
11.1 List of Bacterial Skin Diseases Marketed Drugs Across the Top 7 Markets
11.1.1 Nuzyra (Omadacycline) - Paratek Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Dalvance (Dalbavancin) - Allergan
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Sivextro (Tedizolid ) - Merck Sharp & Dohme
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Kimyrsa (oritavancin) - Melinta Therapeutics
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Vibativ (Telavancin ) - Cumberland Pharmaceuticals
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BACTERIAL SKIN DISEASES - PIPELINE DRUGS
12.1 List of Bacterial Skin Diseases Pipeline Drugs Across the Top 7 Markets
12.1.1 Debio1450 - Debiopharm
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Contezolid acefosamil - MicuRx Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 BC 3781 - Nabriva Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 TNP2092 - TenNor Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BACTERIAL SKIN DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BACTERIAL SKIN DISEASES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BACTERIAL SKIN DISEASES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bacterial Skin Diseases - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bacterial Skin Diseases - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bacterial Skin Diseases - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bacterial Skin Diseases - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bacterial Skin Diseases - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bacterial Skin Diseases - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bacterial Skin Diseases - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bacterial Skin Diseases - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bacterial Skin Diseases - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bacterial Skin Diseases - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bacterial Skin Diseases - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bacterial Skin Diseases - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bacterial Skin Diseases - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bacterial Skin Diseases - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bacterial Skin Diseases - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bacterial Skin Diseases - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bacterial Skin Diseases - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bacterial Skin Diseases - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bacterial Skin Diseases - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bacterial Skin Diseases - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bacterial Skin Diseases - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bacterial Skin Diseases - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bacterial Skin Diseases - Access and Reimbursement Overview
16 BACTERIAL SKIN DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BACTERIAL SKIN DISEASES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BACTERIAL SKIN DISEASES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BACTERIAL SKIN DISEASES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BACTERIAL SKIN DISEASES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BACTERIAL SKIN DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BACTERIAL SKIN DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BACTERIAL SKIN DISEASES - UNMET NEEDS
10 BACTERIAL SKIN DISEASES - KEY ENDPOINTS OF TREATMENT
11 BACTERIAL SKIN DISEASES - MARKETED PRODUCTS
11.1 List of Bacterial Skin Diseases Marketed Drugs Across the Top 7 Markets
11.1.1 Nuzyra (Omadacycline) - Paratek Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Dalvance (Dalbavancin) - Allergan
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Sivextro (Tedizolid ) - Merck Sharp & Dohme
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Kimyrsa (oritavancin) - Melinta Therapeutics
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Vibativ (Telavancin ) - Cumberland Pharmaceuticals
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BACTERIAL SKIN DISEASES - PIPELINE DRUGS
12.1 List of Bacterial Skin Diseases Pipeline Drugs Across the Top 7 Markets
12.1.1 Debio1450 - Debiopharm
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Contezolid acefosamil - MicuRx Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 BC 3781 - Nabriva Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 TNP2092 - TenNor Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BACTERIAL SKIN DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BACTERIAL SKIN DISEASES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BACTERIAL SKIN DISEASES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bacterial Skin Diseases - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bacterial Skin Diseases - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bacterial Skin Diseases - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bacterial Skin Diseases - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bacterial Skin Diseases - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bacterial Skin Diseases - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bacterial Skin Diseases - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bacterial Skin Diseases - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bacterial Skin Diseases - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bacterial Skin Diseases - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bacterial Skin Diseases - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bacterial Skin Diseases - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bacterial Skin Diseases - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bacterial Skin Diseases - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bacterial Skin Diseases - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bacterial Skin Diseases - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bacterial Skin Diseases - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bacterial Skin Diseases - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bacterial Skin Diseases - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bacterial Skin Diseases - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bacterial Skin Diseases - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bacterial Skin Diseases - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bacterial Skin Diseases - Access and Reimbursement Overview
16 BACTERIAL SKIN DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BACTERIAL SKIN DISEASES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BACTERIAL SKIN DISEASES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
